Neuroleptic malignant syndrome during low dosed neuroleptic medication in first-episode psychosis: A case report

Psychopharmacology

Volumn 144, Issue 4, 1999, Pages 416-418

  Gönner, Friedrich ^a   Baumgartner, Ralf ^a   Schüpbach, Daniel ^b   Merlo, Marco C G ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Clozapine; First episode psychosis; Fluphenazine; Low dose medication; Neuroleptic malignant syndrome

Indexed keywords

CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUPHENAZINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BODY TEMPERATURE; CASE REPORT; DOPAMINE RELEASE; DRUG EFFECT; FEMALE; HOSPITAL PATIENT; HUMAN; MENTAL PATIENT; MUSCLE INJURY; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; PSYCHOSIS; THERMOREGULATION;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DANTROLENE; FEMALE; FLUPHENAZINE; HUMANS; MUSCLE RELAXANTS, CENTRAL; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHOTIC DISORDERS;

EID: 0033021436     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130051026     Document Type: Article

References (18)

1. Addonizio G, Susman VL (1991) Neuroleptic malignant syndrome. A clinical approach. Mosby Year Book, St. Louis, Baltimore Boston
2. American Psychiatric Association (1994) Diagnostic and statistical manual for mental disorders, 4th edn. American Psychiatric Press, Washington, D.C., pp 739-742
3. American Psychiatric Association (1997) Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Press, Washington, D.C., p 74
4. Baldessarini RJ (1996) Drugs and the treatment of psychiatric disorders: psychosis and anxiety. In: Hardman JG, Goodman Gilman A, Limbird LE (eds) Goodman and Gilman's The pharmacological basis of therapeutics, 9th edn. McGraw-Hill, New York St. Louis San Francisco, pp 399-430
5. DasGupta K, Young A (1991) Clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry 52:105-107
6. Delay J, Pichot P, Lemperiere MT, Ellisade B, Peigne F (1960) Un neuroleptique majeur non-phenothiazine et non-reserpin, 1'haloperidol, dans le traitment des psychoses. Ann Med Psychol (Paris) 118:145-152
7. Gelenberg AJ, Bellinghausen B, Wojcik JD, Falk WE, Sachs GS (1988) A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry 145:517-518
8. Gratz SS, Levinson DF, Simpson GM (1992) Neuroleptic malignant syndrome. In: Kane JM, Liebermann JA (eds) Adverse effects of psychotropic drugs. Guilford Press, New York London, pp 266-284
9. Jain KK (1996) Drug-induced neurological disorders. Hogrefe and Huber, Seattle Toronto Bern, pp 347-356
10. Keck PE, Pope HG, McElroy SL (1991) Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry 148:880-882
11. Merlo MCG, Gerlach J (1995) Treatment-resistant schizophrenia. Rev Contemp Pharmacother 6:153-164
12. Modestin J, Toffler G, Drescher JP (1992) Neuroleptic malignant syndrome: results of a prospective study. Psychiatry Res 44: 251-256
13. Pelonero AL, Lenvenson, JL, Pandurangi (1998) Neuroleptic malignant syndrome: a review. Psychiatr Serv 49:1163-1172
14. Rosebush PI, Stewart TA (1989) A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 146:717-725
15. Shalev A, Munitz H (1986) The neuroleptic nalignant syndrome: agent and host interaction. Acta Psychiatr Scand 73:337-347
16. Shalev A, Hermesh H, Munitz H (1989) Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 50:18-25
17. Van Kammen DP, Marder SR (1995) Dopamine receptor antagonists. In: Kaplan HI, Sadock BJ (eds) Comprehensive textbook of psychiatry, 6th edn. Williams and Wilkins, Baltimore, pp 2004-2005
18. Weller M, Kornhuber J (1992) Clozapine rechallenge after an episode of "neuroleptic malignant syndrome". Br J Psychiatry 161: 855-856